Deregulated Fcy receptor expression in patients with CIDP

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 5, 2015, Pages e148-

  Quast, Isaak ^a   Cueni, Flavio ^a   Nimmerjahn, Falk ^b   Tackenberg, Bjorn ^c   Lunemann, Jan D ^a,d  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD27 ANTIGEN; FC RECEPTOR; FC RECEPTOR IIA; IMMUNOGLOBULIN;

ADULT; ARTICLE; B LYMPHOCYTE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LEUKOCYTE; MALE; MEMORY CELL; MIDDLE AGED; MONOCYTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT INDICATION;

EID: 85006513832     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000148     Document Type: Article

References (33)

1. Yan WX, Taylor J, Andrias-Kauba S, Pollard JD. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol 2000;47:765-775.
2. Meyer zu Horste G, Hartung HP, Kieseier BC. From bench to bedside-experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol 2007;3:198-211.
3. Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002; 59:S13-S21.
4. Hughes RA, Donofrio P, Bril V, et al; ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008;7:136-144.
5. Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2002;2:580-592.
6. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008;8: 34-47.
7. Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 2005;115:2914-2923.
8. Brownlie RJ, Lawlor KE, Niederer HA, et al. Distinct cell-specific control of autoimmunity and infection by Fcgam-maRIIb. J Exp Med 2008;205:883-895.
9. Tackenberg B, Jelcic I, Baerenwaldt A, et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci USA 2009;106:4788-4792.
10. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19: 604-607.
11. Bruhns P, Samuelsson A, Pollard JW, Ravetch JV. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 2003;18:573-581.
12. Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demy-elinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993;56: 36-39.
13. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56:445-449.
14. Tackenberg B, Lunemann JD, Steinbrecher A, et al. Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy. Neurology 2007;68:1622-1629.
15. Latov N, Deng C, Dalakas MC, et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneurop-athy. Arch Neurol 2010;67:802-807.
16. Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 2000;13:277-285.
17. Mackay M, Stanevsky A, Wang T, et al. Selective dysre-gulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med 2006;203:2157-2164.
18. Su K, Li X, Edberg JC, Wu J, Ferguson P, Kimberly RP. A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcgammaRIIb alters receptor expression and associates with autoimmunity. II. Differential binding of GATA4 and Yin-Yang1 transcription factors and correlated receptor expression and function. J Immunol 2004;172:7192-7199.
19. Olferiev M, Masuda E, Tanaka S, Blank MC, Pricop L. The role of activating protein 1 in the transcriptional regulation of the human FCGR2B promoter mediated by the-343 G-. C polymorphism associated with systemic lupus erythematosus. J Biol Chem 2007;282: 1738-1746.
20. Blank MC, Stefanescu RN, Masuda E, et al. Decreased transcription of the human FCGR2B gene mediated by the-343 G/C promoter polymorphism and association with systemic lupus erythematosus. Hum Genet 2005; 117:220-227.
21. Kikuchi-Taura A, Yura A, Tsuji S, et al. Monocyte CD64 expression as a novel biomarker for the disease activity of systemic lupus erythematosus. Lupus Epub 2015 Mar 24.
22. Madia F, Frisullo G, Nociti V, et al. pSTAT1, pSTAT3, and T-bet as markers of disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2009;14:107-117.
23. Marzo ME, Tintoré M, Fabregues O, Montalbán X, Codina A. Chronic inflammatory demyelinating polyneu-ropathy during treatment with interferon-alpha. J Neurol Neurosurg Psychiatry 1998;65:604.
24. Meriggioli MN, Rowin J. Chronic inflammatory demye-linating polyneuropathy after treatment with interferon-alpha. Muscle Nerve 2000;23:433-435.
25. Anthoney DA, Bone I, Evans TR. Inflammatory demyelin-ating polyneuropathy: a complication of immunotherapy in malignant melanoma. Ann Oncol 2000;11:1197-1200.
26. Hirotani M, Nakano H, Ura S, et al. Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Intern Med 2009;48:373-375.
27. Khiani V, Kelly T, Shibli A, Jensen D, Mohanty SR. Acute inflammatory demyelinating polyneuropathy associ-ated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection. World J Gastroenterol 2008; 14:318-321.
28. Kato-Motozaki Y, Komai K, Takahashi K, et al. Polyethylene glycol interferon alpha-2b-induced immune-mediated polyradiculoneuropathy. Intern Med 2009;48:569-572.
29. Shiga K, Tanaka E, Isayama R, Mizuno T, Itoh K, Nakagawa M. Chronic inflammatory demyelinating poly-neuropathy due to the administration of pegylated inter-feron alpha-2b: a neuropathology case report. Intern Med 2012;51:217-221.
30. Tanaka M, Krutzik SR, Sieling PA, Lee DJ, Rea TH, Modlin RL. Activation of Fc gamma RI on monocytes triggers differentiation into immature dendritic cells that induce autoreactive T cell responses. J Immunol 2009; 183:2349-2355.
31. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484-486.
32. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialyla-tion. Science 2006;313:670-673.
33. Dalakas MC; Medscape. Advances in the diagnosis, path-ogenesis and treatment of CIDP. Nat Rev Neurol 2011;7: 507-517.